Jean-Philippe Rigaud
Research Subjects
Research Interests
Jean-Philippe Rigaud has a total of 333 co-authors. Here are the top co-authors by number of shared publications:
- Jean-Pierre Quenot
Department of Intensive Care, Burgundy University Hospital, Dijon, France
16 shared publications - Nicolas Meunier-Beillard
INSERM, CIC 1432, Module Épidémiologie Clinique, université de Bourgogne-Franche Comté, Dijon, France
8 shared publications - Fiona Ecarnot
SINERGIES, University of Franche-Comté, Besançon, France
7 shared publications - Marie Labruyère
Service de Médecine Intensive-Réanimation, CHU Dijon-Bourgogne, Dijon Cedex, France
7 shared publications - Jean-Baptiste Roudaut
Service de Médecine Intensive-Réanimation, CHU Dijon-Bourgogne, Dijon Cedex, France
5 shared publications - Pascal Andreu
Service de Médecine Intensive-Réanimation, CHU Dijon-Bourgogne, Dijon Cedex, France
5 shared publications
Latest Publications
- Open Access
- 14 July 2026
- Published by MDPI AG in Healthcare
- Vol. 14 (14) , 2105
Impact of Legal Protection on Life-Support Interventions and 3-Month Mortality in the Intensive Care Unit: The Vulne-Rea Study
Background/Objectives: Adults under legal protection experience management delays and prolonged hospitalization. This study investigated whether ICU outcomes differ between patients with versus without legal protection. Methods: This retrospective, single-center study evaluated patients admitted to a French ICU (July 2015–July 2023). Protected patients were compared to autonomous controls matched 1:3 by age and admission year. Results: Of the 1051 patients included, 266 (25.3%) were under legal protection. The protected group had a higher proportion of women (43.2% vs. 35.7%, p = 0.025), received renal replacement therapy less frequently (8.6% vs. 15.4%, p = 0.007), and required non-invasive ventilation more frequently (25.2% vs. 17.2%, p = 0.004) than controls. Three-month mortality was 38.7% in controls versus 33.1% in protected patients, showing no significant difference after multivariable adjustment for 6 prespecified clinical variables (aOR 0.816, 95% CI 0.564 to 1.180). In the adjusted model, higher SAPS II scores and vasopressor use were significantly associated with increased 3-month mortality, whereas non-invasive ventilation and non-respiratory admission indications (sepsis, renal failure, trauma) were associated with decreased mortality. Conclusions: No significant association was observed between the presence of a legal protection measure prior to ICU admission and 3-month patient mortality. However, these results must be interpreted with caution due to a potential lack of statistical power. Additionally, legally protected patients were observed to receive renal replacement therapy less frequently, whereas non-invasive ventilation was utilized more frequently. Within this context, further research is required to evaluate the impact of legal protection status on the formal collegial deliberations that lead to decisions regarding the limitation of life-sustaining treatments.
- 14 July 2026
- Published by MDPI AG in Healthcare
- Vol. 14 (14) , 2105
Open AccessImpact of Legal Protection on Life-Support Interventions and 3-Month Mortality in the Intensive Care Unit: The Vulne-Rea Study
Background/Objectives: Adults under legal protection experience management delays and prolonged hospitalization. This study investigated whether ICU outcomes differ between patients with versus without legal protection. Methods: This retrospective, single-center study evaluated patients admitted to a French ICU (July 2015–July 2023). Protected patients were compared to autonomous controls matched 1:3 by age and admission year. Results: Of the 1051 patients included, 266 (25.3%) were under legal protection. The protected group had a higher proportion of women (43.2% vs. 35.7%, p = 0.025), received renal replacement therapy less frequently (8.6% vs. 15.4%, p = 0.007), and required non-invasive ventilation more frequently (25.2% vs. 17.2%, p = 0.004) than controls. Three-month mortality was 38.7% in controls versus 33.1% in protected patients, showing no significant difference after multivariable adjustment for 6 prespecified clinical variables (aOR 0.816, 95% CI 0.564 to 1.180). In the adjusted model, higher SAPS II scores and vasopressor use were significantly associated with increased 3-month mortality, whereas non-invasive ventilation and non-respiratory admission indications (sepsis, renal failure, trauma) were associated with decreased mortality. Conclusions: No significant association was observed between the presence of a legal protection measure prior to ICU admission and 3-month patient mortality. However, these results must be interpreted with caution due to a potential lack of statistical power. Additionally, legally protected patients were observed to receive renal replacement therapy less frequently, whereas non-invasive ventilation was utilized more frequently. Within this context, further research is required to evaluate the impact of legal protection status on the formal collegial deliberations that lead to decisions regarding the limitation of life-sustaining treatments.
- Open Access
- 1 April 2026
- Published by Springer Nature in Journal of Intensive Care
- Vol. 14 (1) , 34
PICS-SES postintensive care syndrome and socioeconomic status
Postintensive care syndrome (PICS) encompasses physical, psychological, and cognitive sequelae following an intensive care unit (ICU) stay, with repercussi
- 1 April 2026
- Published by Springer Nature in Journal of Intensive Care
- Vol. 14 (1) , 34
Open AccessPICS-SES postintensive care syndrome and socioeconomic status
Postintensive care syndrome (PICS) encompasses physical, psychological, and cognitive sequelae following an intensive care unit (ICU) stay, with repercussi
- 12 December 2025
- Published by Elsevier in Respiratory Medicine and Research
- Vol. 89, 101241
An original story of a coma
- 12 December 2025
- Published by Elsevier in Respiratory Medicine and Research
- Vol. 89, 101241
An original story of a coma
- 20 October 2025
- Published by Springer Nature in Intensive Care Medicine
- Vol. 51 (11) , 2054-2064
Characteristics of ventilator weaning in patients intubated for Guillain–Barré syndrome or myasthenia gravis: a nationwide multicenter study
Purpose Severe forms of Guillain–Barré syndrome (GBS) and myasthenia gravis (MG) may result in prolonged mechanical ventilation in ICUs. Data on weaning from mechanical ventilation are scarce, and our objective was to assess ventilator weaning characteristics in a large-scale multicenter study. Methods Multicenter retrospective cohort study including all patients intubated for at least 48 h for GBS or MG over a 10-year period (from January 2014 to December 2023). The primary outcome was the proportion of patients having experienced prolonged weaning (at least 7 days). Results Some 886 patients admitted to 47 ICUs in France were retained in the analysis, including 513 (58%) with GBS and 373 (42%) with MG. Patients with GBS were more likely to experience prolonged weaning than those with MG (64% vs. 35%, p < 0.001). An extubation attempt was performed in only 46% of patients with GBS and in 88% patients with MG (p < 0.001). Reintubation rates were 26% in patients with GBS and 29% in patients with MG (p = 0.440). Patients with GBS were more likely to undergo tracheostomy than those with MG (57% vs. 17%, p < 0.001). Patients with GBS required a longer duration of mechanical ventilation and ICU stay. Mortality rates were similar (9.4% for patients with GBS and 9.7% for patients with MG, p = 0.882). Conclusions Patients with GBS were more likely to experience prolonged weaning and to undergo tracheostomy than patients with MG. More than one-fourth of patients required reintubation after an extubation attempt. Despite prolonged duration of mechanical ventilation, mortality remained relatively low.
- 20 October 2025
- Published by Springer Nature in Intensive Care Medicine
- Vol. 51 (11) , 2054-2064
Characteristics of ventilator weaning in patients intubated for Guillain–Barré syndrome or myasthenia gravis: a nationwide multicenter study
Purpose Severe forms of Guillain–Barré syndrome (GBS) and myasthenia gravis (MG) may result in prolonged mechanical ventilation in ICUs. Data on weaning from mechanical ventilation are scarce, and our objective was to assess ventilator weaning characteristics in a large-scale multicenter study. Methods Multicenter retrospective cohort study including all patients intubated for at least 48 h for GBS or MG over a 10-year period (from January 2014 to December 2023). The primary outcome was the proportion of patients having experienced prolonged weaning (at least 7 days). Results Some 886 patients admitted to 47 ICUs in France were retained in the analysis, including 513 (58%) with GBS and 373 (42%) with MG. Patients with GBS were more likely to experience prolonged weaning than those with MG (64% vs. 35%, p < 0.001). An extubation attempt was performed in only 46% of patients with GBS and in 88% patients with MG (p < 0.001). Reintubation rates were 26% in patients with GBS and 29% in patients with MG (p = 0.440). Patients with GBS were more likely to undergo tracheostomy than those with MG (57% vs. 17%, p < 0.001). Patients with GBS required a longer duration of mechanical ventilation and ICU stay. Mortality rates were similar (9.4% for patients with GBS and 9.7% for patients with MG, p = 0.882). Conclusions Patients with GBS were more likely to experience prolonged weaning and to undergo tracheostomy than patients with MG. More than one-fourth of patients required reintubation after an extubation attempt. Despite prolonged duration of mechanical ventilation, mortality remained relatively low.
- Open Access
Effect of high-flow nasal cannula oxygen versus standard oxygen on mortality in patients with acute hypoxaemic respiratory failure: protocol for a multicentre, randomised controlled trial (SOHO)
Introduction First-line oxygenation strategy in patients with acute hypoxaemic respiratory failure consists in standard oxygen or high-flow nasal oxygen therapy. Clinical practice guidelines suggest the use of high-flow nasal oxygen rather than standard oxygen. However, findings remain contradictory with a low level of certainty. We hypothesise that compared with standard oxygen, high-flow nasal oxygen may reduce mortality in patients with acute hypoxaemic respiratory failure. Method and analysis The Standard Oxygen versus High-flow nasal Oxygen-trial is an investigator-initiated, multicentre, open-label, randomised controlled trial comparing high-flow nasal oxygen versus standard oxygen in patients admitted to an intensive care unit (ICU) for acute respiratory failure with moderate-to-severe hypoxaemia. 1110 patients will be randomly assigned to one of the two groups with a ratio of 1:1. The primary outcome is the number of patients who died 28 days after randomisation. Secondary outcomes include comfort, dyspnoea and oxygenation 1 hour after treatment initiation, the number of patients intubated at day 28, mortality in ICU, in hospital and until day 90, and complications during ICU stay. Ethics and dissemination The study has been approved by the central Ethics Committee ‘Sud Méditerranée III’ (2020-07-05) and patients will be included after informed consent. The results will be submitted for publication in peer-reviewed journals. Trial registration number NCT04468126.
Open AccessEffect of high-flow nasal cannula oxygen versus standard oxygen on mortality in patients with acute hypoxaemic respiratory failure: protocol for a multicentre, randomised controlled trial (SOHO)
Introduction First-line oxygenation strategy in patients with acute hypoxaemic respiratory failure consists in standard oxygen or high-flow nasal oxygen therapy. Clinical practice guidelines suggest the use of high-flow nasal oxygen rather than standard oxygen. However, findings remain contradictory with a low level of certainty. We hypothesise that compared with standard oxygen, high-flow nasal oxygen may reduce mortality in patients with acute hypoxaemic respiratory failure. Method and analysis The Standard Oxygen versus High-flow nasal Oxygen-trial is an investigator-initiated, multicentre, open-label, randomised controlled trial comparing high-flow nasal oxygen versus standard oxygen in patients admitted to an intensive care unit (ICU) for acute respiratory failure with moderate-to-severe hypoxaemia. 1110 patients will be randomly assigned to one of the two groups with a ratio of 1:1. The primary outcome is the number of patients who died 28 days after randomisation. Secondary outcomes include comfort, dyspnoea and oxygenation 1 hour after treatment initiation, the number of patients intubated at day 28, mortality in ICU, in hospital and until day 90, and complications during ICU stay. Ethics and dissemination The study has been approved by the central Ethics Committee ‘Sud Méditerranée III’ (2020-07-05) and patients will be included after informed consent. The results will be submitted for publication in peer-reviewed journals. Trial registration number NCT04468126.
- Open Access
- 5 December 2023
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 12 (24) , 7509
Ventilatory Management of Patients with Acute Respiratory Distress Syndrome Due to SARS-CoV-2
The emergence of the new SARS-CoV-2 in December 2019 caused a worldwide pandemic of the resultant disease, COVID-19. There was a massive surge in admissions to intensive care units (ICU), notably of patients with hypoxaemic acute respiratory failure. In these patients, optimal oxygen therapy was crucial. In this article, we discuss tracheal intubation to provide mechanical ventilation in patients with hypoxaemic acute respiratory failure due to SARS-CoV-2. We first describe the pathophysiology of respiratory anomalies leading to acute respiratory distress syndrome (ARDS) due to infection with SARS-CoV-2, and then briefly review management, focusing particularly on the ventilation strategy. Overall, the ventilatory management of ARDS due to SARS-CoV-2 infection is largely the same as that applied in ARDS from other causes, and lung-protective ventilation is recommended. The difference lies in the initial clinical presentation, with profound hypoxaemia often observed concomitantly with near-normal pulmonary compliance.
- 5 December 2023
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 12 (24) , 7509
Open AccessVentilatory Management of Patients with Acute Respiratory Distress Syndrome Due to SARS-CoV-2
The emergence of the new SARS-CoV-2 in December 2019 caused a worldwide pandemic of the resultant disease, COVID-19. There was a massive surge in admissions to intensive care units (ICU), notably of patients with hypoxaemic acute respiratory failure. In these patients, optimal oxygen therapy was crucial. In this article, we discuss tracheal intubation to provide mechanical ventilation in patients with hypoxaemic acute respiratory failure due to SARS-CoV-2. We first describe the pathophysiology of respiratory anomalies leading to acute respiratory distress syndrome (ARDS) due to infection with SARS-CoV-2, and then briefly review management, focusing particularly on the ventilation strategy. Overall, the ventilatory management of ARDS due to SARS-CoV-2 infection is largely the same as that applied in ARDS from other causes, and lung-protective ventilation is recommended. The difference lies in the initial clinical presentation, with profound hypoxaemia often observed concomitantly with near-normal pulmonary compliance.
- Open Access
- 27 September 2023
- Published by Springer Nature in Intensive Care Medicine
- Vol. 49 (11) , 1438-1439
Correction: Influence of socio-economic status on functional recovery after ARDS caused by SARS-CoV-2: the multicentre, observational RECOVIDS study
- 27 September 2023
- Published by Springer Nature in Intensive Care Medicine
- Vol. 49 (11) , 1438-1439
Open AccessCorrection: Influence of socio-economic status on functional recovery after ARDS caused by SARS-CoV-2: the multicentre, observational RECOVIDS study
- Open Access
- 24 August 2023
- Published by Springer Nature in Intensive Care Medicine
- Vol. 49 (10) , 1168-1180
Influence of socio-economic status on functional recovery after ARDS caused by SARS-CoV-2: the multicentre, observational RECOVIDS study
Purpose Survivors after acute respiratory distress syndrome (ARDS) due to coronavirus disease 2019 (COVID-19) are at high risk of developing respiratory sequelae and functional impairment. The healthcare crisis caused by the pandemic hit socially disadvantaged populations. We aimed to evaluate the influence of socio-economic status on respiratory sequelae after COVID-19 ARDS. Methods We carried out a prospective multicenter study in 30 French intensive care units (ICUs), where ARDS survivors were pre-enrolled if they fulfilled the Berlin ARDS criteria. For patients receiving high flow oxygen therapy, a flow ≥ 50 l/min and an FiO2 ≥ 50% were required for enrollment. Socio-economic deprivation was defined by an EPICES (Evaluation de la Précarité et des Inégalités de santé dans les Centres d’Examens de Santé - Evaluation of Deprivation and Inequalities in Health Examination Centres) score ≥ 30.17 and patients were included if they performed the 6-month evaluation. The primary outcome was respiratory sequelae 6 months after ICU discharge, defined by at least one of the following criteria: forced vital capacity < 80% of theoretical value, diffusing capacity of the lung for carbon monoxide < 80% of theoretical value, oxygen desaturation during a 6-min walk test and fibrotic-like findings on chest computed tomography. Results Among 401 analyzable patients, 160 (40%) were socio-economically deprived and 241 (60%) non-deprived; 319 (80%) patients had respiratory sequelae 6 months after ICU discharge (81% vs 78%, deprived vs non-deprived, respectively). No significant effect of socio-economic status was identified on lung sequelae (odds ratio (OR), 1.19 [95% confidence interval (CI), 0.72–1.97]), even after adjustment for age, sex, most invasive respiratory support, obesity, most severe P/F ratio (adjusted OR, 1.02 [95% CI 0.57–1.83]). Conclusions In COVID-19 ARDS survivors, socio-economic status had no significant influence on respiratory sequelae 6 months after ICU discharge.
- 24 August 2023
- Published by Springer Nature in Intensive Care Medicine
- Vol. 49 (10) , 1168-1180
Open AccessInfluence of socio-economic status on functional recovery after ARDS caused by SARS-CoV-2: the multicentre, observational RECOVIDS study
Purpose Survivors after acute respiratory distress syndrome (ARDS) due to coronavirus disease 2019 (COVID-19) are at high risk of developing respiratory sequelae and functional impairment. The healthcare crisis caused by the pandemic hit socially disadvantaged populations. We aimed to evaluate the influence of socio-economic status on respiratory sequelae after COVID-19 ARDS. Methods We carried out a prospective multicenter study in 30 French intensive care units (ICUs), where ARDS survivors were pre-enrolled if they fulfilled the Berlin ARDS criteria. For patients receiving high flow oxygen therapy, a flow ≥ 50 l/min and an FiO2 ≥ 50% were required for enrollment. Socio-economic deprivation was defined by an EPICES (Evaluation de la Précarité et des Inégalités de santé dans les Centres d’Examens de Santé - Evaluation of Deprivation and Inequalities in Health Examination Centres) score ≥ 30.17 and patients were included if they performed the 6-month evaluation. The primary outcome was respiratory sequelae 6 months after ICU discharge, defined by at least one of the following criteria: forced vital capacity < 80% of theoretical value, diffusing capacity of the lung for carbon monoxide < 80% of theoretical value, oxygen desaturation during a 6-min walk test and fibrotic-like findings on chest computed tomography. Results Among 401 analyzable patients, 160 (40%) were socio-economically deprived and 241 (60%) non-deprived; 319 (80%) patients had respiratory sequelae 6 months after ICU discharge (81% vs 78%, deprived vs non-deprived, respectively). No significant effect of socio-economic status was identified on lung sequelae (odds ratio (OR), 1.19 [95% confidence interval (CI), 0.72–1.97]), even after adjustment for age, sex, most invasive respiratory support, obesity, most severe P/F ratio (adjusted OR, 1.02 [95% CI 0.57–1.83]). Conclusions In COVID-19 ARDS survivors, socio-economic status had no significant influence on respiratory sequelae 6 months after ICU discharge.
- Open Access
- 17 June 2023
- Published by Elsevier in Annals of Intensive Care
- Vol. 13 (1) , 53-13
Insulin therapy and blood glucose management in critically ill patients: a 1-day cross-sectional observational study in 69 French intensive care units
- 17 June 2023
- Published by Elsevier in Annals of Intensive Care
- Vol. 13 (1) , 53-13
Open AccessInsulin therapy and blood glucose management in critically ill patients: a 1-day cross-sectional observational study in 69 French intensive care units
- Open Access
- 27 February 2023
- Published by MDPI AG in Healthcare
- Vol. 11 (5) , 707
Patient Information and Consent for Care in the Intensive Care Unit
In this paper, we review the ethical issues involved in providing information to, and obtaining consent (for treatment and/or research) from patients in the intensive care unit. We first review the ethical obligations of the physician in treating patients, who are by definition, vulnerable, and often unable to assert their autonomy during situations of critical illness. Providing clear and transparent information to the patient about treatment options or research opportunities is an ethical and, in some cases, legal obligation for the physicians, but may be rendered difficult, not to say impossible in the intensive care unit by the patient’s health state. In this context, we review the specificities of intensive care with respect to information and consent. We discuss who the right contact person is in the ICU setting, with possible choices including a surrogate decision maker, or a member of the family, in the absence of an officially designated surrogate. We further review the specific considerations relating to the family of critically ill patients, and the amount and type of information that may be given to them without breaching the tenets of medical confidentiality. Finally, we discuss the specific cases of consent to research, and patients who refuse care.
- 27 February 2023
- Published by MDPI AG in Healthcare
- Vol. 11 (5) , 707
Open AccessPatient Information and Consent for Care in the Intensive Care Unit
In this paper, we review the ethical issues involved in providing information to, and obtaining consent (for treatment and/or research) from patients in the intensive care unit. We first review the ethical obligations of the physician in treating patients, who are by definition, vulnerable, and often unable to assert their autonomy during situations of critical illness. Providing clear and transparent information to the patient about treatment options or research opportunities is an ethical and, in some cases, legal obligation for the physicians, but may be rendered difficult, not to say impossible in the intensive care unit by the patient’s health state. In this context, we review the specificities of intensive care with respect to information and consent. We discuss who the right contact person is in the ICU setting, with possible choices including a surrogate decision maker, or a member of the family, in the absence of an officially designated surrogate. We further review the specific considerations relating to the family of critically ill patients, and the amount and type of information that may be given to them without breaching the tenets of medical confidentiality. Finally, we discuss the specific cases of consent to research, and patients who refuse care.